Developments in renal pharmacogenomics and applications in chronic kidney disease

References

• LeveyASAtkinsRCoreshJChronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global OutcomesKidney Int200772324725917568785
   PubMed Web of Science ®Google Scholar
• TaalMWChronic Kidney Disease in General Populations and Primary CareCurr Opin Nephrol Hypertens201322659359824104481
   PubMed Web of Science ®Google Scholar
• JhaVGarcia-GarciaGIsekiKChronic kidney disease: global dimension and perspectivesLancet2013382988826027223727169
   PubMed Web of Science ®Google Scholar
• BallSLloydJCairnsTWhy is there so much end-stage renal failure of undetermined cause in UK Indo-Asians?QJM200194418719311294961
   PubMed Web of Science ®Google Scholar
• KronenbergFEmerging risk factors and markers of chronic kidney disease progressionNat Rev Nephrol200951267768919935815
   PubMed Web of Science ®Google Scholar
• HallanSICoreshJAstorBCInternational comparison of the relationship of chronic kidney disease prevalence and ESRD riskJ Am Soc Nephrol20061782275228416790511
   PubMed Web of Science ®Google Scholar
• ChadbanSJBrigantiEMKerrPGPrevalence of kidney damage in Australian adults: The AusDiab kidney studyJ Am Soc Nephrol2003147 Suppl 2S131S13812819318
   PubMed Web of Science ®Google Scholar
• BowlingCBInkerLAGutiérrezOMAge-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complicationsClin J Am Soc Nephrol20116122822282822034504
   PubMed Web of Science ®Google Scholar
• DalrympleLSMohammedSMMuYRisk of cardiovascular events after infection-related hospitalizations in older patients on dialysisClin J Am Soc Nephrol2011671708171321566109
   PubMed Web of Science ®Google Scholar
• GoASChertowGMFanDMcCullochCEHsuCYChronic kidney disease and the risks of death, cardiovascular events, and hospitalizationN Engl J Med2004351131296130515385656
   PubMed Web of Science ®Google Scholar
• CoreshJSelvinEStevensLAPrevalence of chronic kidney disease in the United StatesJAMA2007298172038204717986697
   PubMed Web of Science ®Google Scholar
• OteroAde FranciscoAGayosoPGarcíaFEPIRCE Study GroupPrevalence of chronic renal disease in Spain: results of the EPIRCE studyNefrologia2010301788620038967
   PubMed Web of Science ®Google Scholar
• TaalMWScreening for chronic kidney disease: preventing harm or harming the healthy?PLoS Med2012911e100134523185137
   PubMed Web of Science ®Google Scholar
• HallanSIVikseBERelationship between chronic kidney disease prevalence and end-stage renal disease riskCurr Opin Nephrol Hypertens200817328629118408480
   PubMed Web of Science ®Google Scholar
• BochudMBurnierMGuessousITop Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular MedicineCurr Pharmacogenomics Person Med20119429932223049672
   PubMedGoogle Scholar
• FoleyRNCollinsAJEnd-stage renal disease in the United States: an update from the United States Renal Data SystemJ Am Soc Nephrol200718102644264817656472
   PubMed Web of Science ®Google Scholar
• DrawzPESedorJRThe genetics of common kidney disease: a pathway toward clinical relevanceNat Rev Nephrol20117845846821712849
   PubMed Web of Science ®Google Scholar
• RuggenentiPCravediPRemuzziGThe RAAS in the pathogenesis and treatment of diabetic nephropathyNat Rev Nephrol20106631933020440277
   PubMed Web of Science ®Google Scholar
• RossingPHommelESmidtUMParvingHHReduction in albuminuria predicts diminished progression in diabetic nephropathyKidney Int Suppl199445S145S1498158884
   PubMed Web of Science ®Google Scholar
• ApperlooAJde ZeeuwDde JongPEShort-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal diseaseKidney Int Suppl199445S174S1788158890
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGBainRPRohdeRDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study GroupN Engl J Med199332920145614628413456
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• SowersJRWhaley-ConnellAEpsteinMNarrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertensionAnn Intern Med20091501177678319487712
   PubMed Web of Science ®Google Scholar
• RusterCWolfGRenin-angiotensin-aldosterone system and progression of renal diseaseJ Am Soc Nephrol200617112985299117035613
   PubMed Web of Science ®Google Scholar
• TaalMWBrennerBMRenoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonistsKidney Int20005751803181710792600
   PubMed Web of Science ®Google Scholar
• LiuSVaziriNDRole of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndromeNephrol Dial Transplant201429353854324166456
   PubMed Web of Science ®Google Scholar
• LevinABakrisGLMolitchMPrevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney diseaseKidney Int2007711313817091124
   PubMed Web of Science ®Google Scholar
• WolfMBetancourtJChangYImpact of activated vitamin D and race on survival among hemodialysis patientsJ Am Soc Nephrol20081971379138818400938
   PubMed Web of Science ®Google Scholar
• TanXLiYLiuYParicalcitol attenuates renal interstitial fibrosis in obstructive nephropathyJ Am Soc Nephrol200617123382339317082242
   PubMed Web of Science ®Google Scholar
• MakibayashiKTatematsuMHirataMA vitamin D analog ameliorates glomerular injury on rat glomerulonephritisAm J Pathol200115851733174111337371
   PubMed Web of Science ®Google Scholar
• FishbaneSChittineniHPackmanMDutkaPAliNDurieNOral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trialAm J Kidney Dis200954464765219596163
   PubMed Web of Science ®Google Scholar
• SzetoCCChowKMKwanBCChungKYLeungCBLiPKOral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trialAm J Kidney Dis200851572473118436082
   PubMed Web of Science ®Google Scholar
• BonizziGKarinMThe two NF-kappaB activation pathways and their role in innate and adaptive immunityTrends Immunol200425628028815145317
   PubMed Web of Science ®Google Scholar
• ResnickLMMüllerFBLaraghJHCalcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolismAnn Intern Med198610556496543532893
   PubMed Web of Science ®Google Scholar
• LiYCKongJWeiMChenZFLiuSQCaoLP1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin systemJ Clin Invest2002110222923812122115
   PubMed Web of Science ®Google Scholar
• GuijarroCEgidoJTranscription factor-kappa B (NF-kappa B) and renal diseaseKidney Int200159241542411168923
   PubMed Web of Science ®Google Scholar
• RichartTLiYStaessenJARenal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertensionAm J Hypertens20072091007101517765144
   PubMed Web of Science ®Google Scholar
• SanadaHJonesJEJosePAGenetics of salt-sensitive hypertensionCurr Hypertens Rep2011131556621058046
   PubMed Web of Science ®Google Scholar
• Lambers HeerspinkHJHoltkampFAParvingHHModeration of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockersKidney Int201282333033722437412
   PubMed Web of Science ®Google Scholar
• VegterSPernaAPostmaMJNavisGRemuzziGRuggenentiPSodium intake, ACE inhibition, and progression to ESRDJ Am Soc Nephrol201223116517322135311
   PubMed Web of Science ®Google Scholar
• TurnerJMBauerCAbramowitzMKMelamedMLHostetterTHTreatment of chronic kidney diseaseKidney Int201281435136222166846
   PubMed Web of Science ®Google Scholar
• PergolaPEKrauthMHuffJWEffect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKDAm J Nephrol201133546947621508635
   PubMed Web of Science ®Google Scholar
• PergolaPERaskinPTotoRDBardoxolone methyl and kidney function in CKD with type 2 diabetesN Engl J Med2011365432733621699484
   PubMed Web of Science ®Google Scholar
• IndraccoloUBarbieriFEffect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observationsEur J Obstet Gynecol Reprod Biol20101501767920176435
   PubMed Web of Science ®Google Scholar
• TruiniABiasiottaADi StefanoGPalmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathyCNS Neurol Disord Drug Targets201110891692022229320
   PubMed Web of Science ®Google Scholar
• YoshiharaDKugitaMYamaguchiTGlobal Gene Expression Profiling in PPAR-γ Agonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney DiseasePPAR Res2012201269589822666229
   PubMed Web of Science ®Google Scholar
• ParkCWZhangYZhangXPPARalpha agonist fenofibrate improves diabetic nephropathy in db/db miceKidney Int20066991511151716672921
   PubMed Web of Science ®Google Scholar
• MerkDSchubert-ZsilaveczMNew hope or drawbacks: will chronic kidney disease be treatable with small molecules in the near future?Future Med Chem20124326927122393934
   PubMed Web of Science ®Google Scholar
• WangLMcLeodHLWeinshilboumRMGenomics and drug responseN Engl J Med2011364121144115321428770
   PubMed Web of Science ®Google Scholar
• RahmiogluNHeatonJClementGGenetic epidemiology of induced CYP3A4 activityPharmacogenet Genomics2011211064265121750469
   PubMed Web of Science ®Google Scholar
• SoderlandPLovekarSWeinerDEBrooksDRKaufmanJSChronic kidney disease associated with environmental toxins and exposuresAdv Chronic Kidney Dis201017325426420439094
   PubMed Web of Science ®Google Scholar
• RajapurkarMMJohnGTKirpalaniALWhat do we know about chronic kidney disease in India: first report of the Indian CKD registryBMC Nephrol2012131022390203
   PubMed Web of Science ®Google Scholar
• WangXLGrecoMSimASDuarteNWangJWilckenDEEffect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetesAtherosclerosis2002162239139711996959
   PubMed Web of Science ®Google Scholar
• SergentanisTNEconomopoulosKPFour polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysisBreast Cancer Res Treat2010122245946920035380
   PubMed Web of Science ®Google Scholar
• WrightCMLarsenJEColosimoMLGenetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancerEur Respir J201035115215919608585
   PubMed Web of Science ®Google Scholar
• ChenJChengMYiLJiangCBRelationship between CYP1A1 genetic polymorphisms and renal cancer in ChinaAsian Pac J Cancer Prev20111292163216622296350
   PubMedGoogle Scholar
• SiddarthMDattaSKAhmedRSBanerjeeBDKalraOPTripathiAKAssociation of CYP1A1 gene polymorphism with chronic kidney disease: a case control studyEnviron Toxicol Pharmacol201336116417023619522
   PubMed Web of Science ®Google Scholar
• SobtiRCSharmaSJoshiAJindalSKJanmejaAGenetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a North Indian populationMol Cell Biochem20042661–21915646021
   PubMed Web of Science ®Google Scholar
• SreejaLSyamalaVHariharanSMadhavanJDevanSCAnkathilRPossible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphism in lung cancer susceptibility in a south Indian populationJ Hum Genet2005501261862716228113
   PubMed Web of Science ®Google Scholar
• AnantharamanDChaubalPMKannanSBhiseyRAMahimkarMBSusceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure a risk modulatorCacinogenesis200728714551462
   Web of Science ®Google Scholar
• GunesADahlMLVariation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphismsPharmacogenomics20089562563718466106
   PubMed Web of Science ®Google Scholar
• HallbergPKarlssonJKurlandLThe CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trialJ Hypertens200220102089209312359989
   PubMed Web of Science ®Google Scholar
• CornelisMCMondaKLYuKGenome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumptionPLoS Genet201174e100203321490707
   PubMed Web of Science ®Google Scholar
• NoordzijMUiterwaalCSArendsLRKokFJGrobbeeDEGeleijnseJMBlood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trialsJ Hypertens200523592192815834273
   PubMed Web of Science ®Google Scholar
• KlagMJWangNYMeoniLACoffee intake and risk of hypertension: the Johns Hopkins precursors studyArch Intern Med2002162665766211911719
   PubMedGoogle Scholar
• WinkelmayerWCStampferMJWillettWCCurhanGCHabitual caffeine intake and the risk of hypertension in womenJAMA2005294182330233516278361
   PubMed Web of Science ®Google Scholar
• BochudMBovetPBurnierMEapCBCYP3A5 and ABCB1 genes and hypertensionPharmacogenomics200910347748719290795
   PubMed Web of Science ®Google Scholar
• WilkinsonGRDrug metabolism and variability among patients in drug responseN Engl J Med2005352212211222115917386
   PubMed Web of Science ®Google Scholar
• SiestGJeannessonEVisvikis-SiestSEnzymes and pharmacogenetics of cardiovascular drugsClin Chim Acta20073811263117362901
   PubMed Web of Science ®Google Scholar
• DalyAKSignificance of the minor cytochrome P450 3A isoformsClin Pharmacokinet2006451133116430309
   PubMed Web of Science ®Google Scholar
• WillrichMAHirataMHHirataRDStatin regulation of CYP3A4 and CYP3A5 expressionPharmacogenomics20091061017102419530969
   PubMed Web of Science ®Google Scholar
• JinYWangYHMiaoJCytochrome P450 3A5 genotype is associated with verapamil response in healthy subjectsClin Pharmacol Ther200782557958517443134
   PubMed Web of Science ®Google Scholar
• EapCBBochudMElstonRCCYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by saltHypertension20074951007101417372036
   PubMed Web of Science ®Google Scholar
• KimKAParkPWLeeOJEffect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjectsClin Pharmacol Ther200680664665617178265
   PubMed Web of Science ®Google Scholar
• KimRBDrugs as P-glycoprotein substrates, inhibitors, and inducersDrug Metab Rev2002341–2475411996011
   PubMed Web of Science ®Google Scholar
• LlaudóIColomHGiménez-BonaféPDo drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony studyTranspl Int201326217718623216707
   PubMed Web of Science ®Google Scholar
• LiuMLiYCitterioLA functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in ChineseAm J Hypertens201326121428143623926124
   PubMed Web of Science ®Google Scholar
• BurkOArnoldKAGeickATegudeHEichelbaumMA role for constitutive androstane receptor in the regulation of human intestinal MDR1 expressionBiol Chem2005386650351316006237
   PubMed Web of Science ®Google Scholar
• TachibanaSYoshinariKChikadaTToriyabeTNagataKYamazoeYInvolvement of Vitamin D receptor in the intestinal induction of human ABCB1Drug Metab Dispos20093781604161019460946
   PubMed Web of Science ®Google Scholar
• SaekiMKuroseKTohkinMHasegawaRIdentification of the functional vitamin D response elements in the human MDR1 geneBiochem Pharmacol200876453154218602086
   PubMed Web of Science ®Google Scholar
• ChowECDurkMRCumminsCLPangKS1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(−/−) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivoJ Pharmacol Exp Ther2011337384685921421739
   PubMed Web of Science ®Google Scholar
• KumarRSchaeferJGrandeJPRochePCImmunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidneyAm J Physiol19942663 Pt 2F477F4858160797
   PubMed Web of Science ®Google Scholar
• SchusterICytochromes P450 are essential players in the vitamin D signaling systemBiochim Biophys Acta20111814118619920619365
   PubMed Web of Science ®Google Scholar
• WangTTTavera-MendozaLELaperriereDLarge-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genesMol Endocrinol200519112685269516002434
   PubMed Web of Science ®Google Scholar
• MakishimaMLuTTXieWVitamin D receptor as an intestinal bile acid sensorScience200229655711313131612016314
   PubMed Web of Science ®Google Scholar
• BarthelTKMathernDRWhitfieldGK1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolismJ Steroid Biochem Mol Biol20071033–538138817293108
   PubMed Web of Science ®Google Scholar
• SantoroDCaccamoDGagliostroGVitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patientsJ Nephrol201326463664422976524
   PubMed Web of Science ®Google Scholar
• GrzegorzewskaAEOstromeckiGGene polymorphism of the vitamin D receptor, vitamin D-binding protein and calcium-sensing receptor in respect of calcium-phosphate disturbances in chronic dialysis patientsPrzegl Lek2013709735738 Polish24455835
   PubMedGoogle Scholar
• de SouzaCMBraosiAPLuczyszynSMAssociation between vitamin D receptor gene polymorphisms and susceptibility to chronic kidney disease and periodontitisBlood Purif2007255–641141917914260
   PubMed Web of Science ®Google Scholar
• Vélayoudom-CéphiseFLLariflaLDonnetJPVitamin D deficiency, vitamin D receptor gene polymorphisms and cardiovascular risk factors in Caribbean patients with type 2 diabetesDiabetes Metab201137654054521764620
   PubMed Web of Science ®Google Scholar
• AlborziPPatelNAPetersonCParicalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trialHypertension200852224925518606901
   PubMed Web of Science ®Google Scholar
• AgarwalRAcharyaMTianJAntiproteinuric effect of oral paricalcitol in chronic kidney diseaseKidney Int20056862823282816316359
   PubMed Web of Science ®Google Scholar
• de ZeeuwDAgarwalRAmdahlMSelective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialLancet201037697521543155121055801
   PubMed Web of Science ®Google Scholar
• LeviMNuclear receptors in renal diseaseBiochim Biophys Acta2011181281061106721511032
   PubMed Web of Science ®Google Scholar
• GardPRImplications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot reviewInt J Mol Epidemiol Genet20101214515721537387
   PubMedGoogle Scholar
• Sayed-TabatabaeiFAOostraBAIsaacsAvan DuijnCMWittemanJCACE polymorphismsCirc Res20069891123113316690893
   PubMed Web of Science ®Google Scholar
• KramersCDanilovSMDeinumJPoint mutation in the stalk of angiotensin-converting enzyme causes a dramatic increase in serum angiotensin-converting enzyme but no cardiovascular diseaseCirculation2001104111236124011551873
   PubMed Web of Science ®Google Scholar
• RiederMJTaylorSLClarkAGNickersonDASequence variation in the human angiotensin converting enzymeNat Genet1999221596210319862
   PubMed Web of Science ®Google Scholar
• RuggenentiPBettinaglioPPinaresFRemuzziGAngiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathiesClin J Am Soc Nephrol2008351511152518550651
   PubMed Web of Science ®Google Scholar
• SantosPCKriegerJEPereiraACRenin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implicationsJ Pharmacol Sci20121202778823079502
   PubMed Web of Science ®Google Scholar
• PennoGChaturvediNTalmudPJEffect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDMDiabetes1998479150715119726242
   PubMed Web of Science ®Google Scholar
• UedaSMeredithPAMortonJJConnellJMElliottHLACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humansCirculation19989820214821539815869
   PubMed Web of Science ®Google Scholar
• JacobsenPRossingKRossingPAngiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathyKidney Int1998534100210069551410
   PubMed Web of Science ®Google Scholar
• JacobsenPTarnowLCarstensenBHovindPPoirierOParvingHHGenetic variation in the Renin-Angiotensin system and progression of diabetic nephropathyJ Am Soc Nephrol200314112843285014569094
   PubMed Web of Science ®Google Scholar
• ParvingHHde ZeeuwDCooperMEACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathyJ Am Soc Nephrol200819477177918199798
   PubMed Web of Science ®Google Scholar
• SoWYMaRCOzakiRAngiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients – interaction with ACE insertion/deletion polymorphismKidney Int20066981438144316395257
   PubMed Web of Science ®Google Scholar
• FilighedduFArgiolasGBullaEClinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in SardiniansPharmacogenomics20089101419142718855530
   PubMed Web of Science ®Google Scholar
• YuHZhangYLiuGRelationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patientsHypertens Res2003261188188614714579
   PubMed Web of Science ®Google Scholar
• ArnettDKDavisBRFordCEPharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) studyCirculation2005111253374338315967849
   PubMed Web of Science ®Google Scholar
• NonoguchiHNakayamaYShiigaiTLow-responders to angiotensin II receptor blockers and genetic polymorphism in angiotensin-converting enzymeClin Nephrol200768420921517969487
   PubMed Web of Science ®Google Scholar
• AdlerSRenal disease: environment, race, or genes?Ethn Dis2006162 Suppl 2S2-35-3916774008
   PubMed Web of Science ®Google Scholar
• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• IbrahimMMDamascenoAHypertension in developing countriesLancet2012380984161161922883510
   PubMed Web of Science ®Google Scholar
• ShawJESicreeRAZimmetPZGlobal estimates of the prevalence of diabetes for 2010 and 2030Diabetes Res Clin Pract201087141419896746
   PubMed Web of Science ®Google Scholar
• WangYMiJShanXYWangQJGeKYIs China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in ChinaInt J Obes (Lond)200731117718816652128
   PubMed Web of Science ®Google Scholar
• HallMEdo CarmoJMda SilvaAAJuncosLAWangZHallJEObesity, hypertension, and chronic kidney diseaseInt J Nephrol Renovasc Dis20147758824600241
   PubMedGoogle Scholar
• KöttgenAPattaroCBögerCANew loci associated with kidney function and chronic kidney diseaseNat Genet201042537638420383146
   PubMed Web of Science ®Google Scholar
• SummersSASteinmetzOMOoiJDToll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritisAm J Pathol201017752234224420847283
   PubMed Web of Science ®Google Scholar
• SummersSAHoiASteinmetzOMTLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathyJ Autoimmun201035429129820810248
   PubMed Web of Science ®Google Scholar
• BochudPYHersbergerMTaffePPolymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infectionAIDS200721444144617301562
   PubMed Web of Science ®Google Scholar
• KrayenbuehlPAHersbergerMTruningerKToll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosisEur J Gastroenterol Hepatol201022783584119809335
   PubMed Web of Science ®Google Scholar
• YangHYLuKCLeeHSRole of the functional Toll-Like receptor-9 promoter polymorphism (−1237T/C) in increased risk of end-stage renal disease: a case-control studyPLoS One201383e5844423472199
   PubMed Web of Science ®Google Scholar
• Jimenez-SousaMALópezEFernandez-RodriguezAGenetic polymorphisms located in genes related to immune and inflammatory processes are associated with end-stage renal disease: a preliminary studyBMC Med Genet2012135822817530
   PubMed Web of Science ®Google Scholar
• SinghVJaiswalPKTiwariPKapoorRMittalRDAssociation of chemokine gene variants with end stage renal disease in North Indian populationTranspl Immunol201328418919223615182
   PubMed Web of Science ®Google Scholar
• NabrdalikKGumprechtJAdamczykPGórczyńska-KosiorzSZywiecJGrzeszczakWAssociation of rs1800471 polymorphism of TGFB1 gene with chronic kidney disease occurrence and progression and hypertension appearanceArch Med Sci20139223023723671432
   PubMed Web of Science ®Google Scholar
• BuraczynskaMBaranowicz-GaszczykIBorowiczEKsiazekATGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetesNephron Physiol20071064p69p7517622752
   PubMedGoogle Scholar
• CollECormandBCamposBAssociation of TGF-beta1 polymorphisms with chronic renal diseaseJ Nephrol200417679479915593053
   PubMed Web of Science ®Google Scholar
• NgDPWarramJHKrolewskiASTGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variantsAm J Kidney Dis2003411222812500218
   PubMed Web of Science ®Google Scholar
• McKnightAJSavageDAPattersonCCSadlierDMaxwellAPResequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathyBMC Med Genet20078517319955
   PubMed Web of Science ®Google Scholar
• BabelNGabdrakhmanovaLHammerMHPredictive value of cytokine gene polymorphisms for the development of end-stage renal diseaseJ Nephrol200619680280717173255
   PubMed Web of Science ®Google Scholar
• YuZYChenLSZhangLCZhouTBMeta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathyNephrology (Carlton)201217548048722385293
   PubMed Web of Science ®Google Scholar
• ZhouTBYinSSQinYHAssociation of angiotensinogen M235T gene polymorphism with end-stage renal disease risk: a meta-analysisMol Biol Rep201340276577223065231
   PubMed Web of Science ®Google Scholar
• SilvaPSFontanaVLuizonMReNOS and BDKRB2 genotypes affect the antihypertensive responses to enalaprilEur J Clin Pharmacol201369216717722706620
   PubMed Web of Science ®Google Scholar
• BeharDMRossetSTzurSAfrican ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic AmericansHum Mol Genet20101991816182720144966
   PubMed Web of Science ®Google Scholar
• FreedmanBIHicksPJBostromMANon-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRDNephrol Dial Transplant200924113366337119567477
   PubMed Web of Science ®Google Scholar
• FreedmanBIHicksPJBostromMAPolymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African AmericansKidney Int200975773674519177153
   PubMed Web of Science ®Google Scholar
• KaoWHKlagMJMeoniLAMYH9 is associated with nondiabetic end-stage renal disease in African AmericansNat Genet200840101185119218794854
   PubMed Web of Science ®Google Scholar
• KoppJBSmithMWNelsonGWMYH9 is a major-effect risk gene for focal segmental glomerulosclerosisNat Genet200840101175118418794856
   PubMed Web of Science ®Google Scholar
• CookeJNBostromMAHicksPJPolymorphisms in MYH9 are associated with diabetic nephropathy in European AmericansNephrol Dial Transplant20122741505151121968013
   PubMed Web of Science ®Google Scholar
• MatshaTEMasconiKYakoYYPolymorphisms in the non-muscle myosin heavy chain gene (MYH9) are associated with lower glomerular filtration rate in mixed ancestry diabetic subjects from South AfricaPLoS One2012712e5252923285077
   PubMed Web of Science ®Google Scholar
• TaviraBCotoEGómezJAssociation between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohortGene20135201737623470845
   PubMed Web of Science ®Google Scholar
• FreedmanBIKoppJBLangefeldCDThe apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African AmericansJ Am Soc Nephrol20102191422142620688934
   PubMed Web of Science ®Google Scholar
• GenoveseGFriedmanDJRossMDAssociation of trypanolytic ApoL1 variants with kidney disease in African AmericansScience2010329599384184520647424
   PubMed Web of Science ®Google Scholar
• GenoveseGTonnaSJKnobAUA risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9Kidney Int201078769870420668430
   PubMed Web of Science ®Google Scholar
• TzurSRossetSShemerRMissense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 geneHum Genet2010128334535020635188
   PubMed Web of Science ®Google Scholar
• O’SeaghdhaCMParekhRSHwangSJThe MYH9/APOL1 region and chronic kidney disease in European-AmericansHum Mol Genet201120122450245621429915
   PubMed Web of Science ®Google Scholar
• WitaspANordforsLCarreroJJGenetic studies in chronic kidney disease: interpretation and clinical applicabilityJ Nephrol201225685186423042432
   PubMed Web of Science ®Google Scholar
• PriorTWCarrier screening for spinal muscular atrophyGenet Med2008101184084218941424
   PubMed Web of Science ®Google Scholar
• MillerDTAdamMPAradhyaSConsensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomaliesAm J Hum Genet201086574976420466091
   PubMed Web of Science ®Google Scholar
• RobsonMOffitKClinical practice. Management of an inherited predisposition to breast cancerN Engl J Med2007357215416217625127
   PubMed Web of Science ®Google Scholar
• FruehFWAmurSMummaneniPPharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug usePharmacotherapy200828899299818657016
   PubMed Web of Science ®Google Scholar
• WienkersLCHeathTGPredicting in vivo drug interactions from in vitro drug discovery dataNat Rev Drug Discov200541082583316224454
   PubMed Web of Science ®Google Scholar
• MolanaeiHCarreroJJHeimbürgerOInfluence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal diseaseEur J Clin Pharmacol201066326927319940985
   PubMed Web of Science ®Google Scholar
• van EssenGGRensmaPLde ZeeuwDAssociation between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapyLancet1996347899494958538349
   PubMed Web of Science ®Google Scholar
• CarreroJJQureshiARPariniPLow serum testosterone increases mortality risk among male dialysis patientsJ Am Soc Nephrol200920361362019144759
   PubMed Web of Science ®Google Scholar
• MuntingheFLVerduijnMZuurmanMWCCR5 deletion protects against inflammation-associated mortality in dialysis patientsJ Am Soc Nephrol20092071641164919389855
   PubMed Web of Science ®Google Scholar
• MuntingheFLVegterSVerduijnMUsing a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patientsPharmacogenet Genomics201121741742521597398
   PubMed Web of Science ®Google Scholar
• BoardPCogganMJohnstonPRossVSuzukiTWebbGGenetic heterogeneity of the human glutathione transferases: a complex of gene familiesPharmacol Ther19904833573692084706
   PubMed Web of Science ®Google Scholar
• RybergDSkaugVHewerAGenotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer riskCarcinogenesis1997187128512899230269
   PubMed Web of Science ®Google Scholar
• LinYSHungSCWeiYHTarngDCGST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patientsJ Am Soc Nephrol200920240541519056870
   PubMed Web of Science ®Google Scholar
• FiliopoulosVVlassopoulosDInflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomesInflamm Allergy Drug Targets20098536938220025585
   PubMedGoogle Scholar
• NordforsLLindholmBStenvinkelPEnd-stage renal disease – not an equal opportunity disease: the role of genetic polymorphismsJ Intern Med2005258111215953127
   PubMed Web of Science ®Google Scholar
• StenvinkelPChronic kidney disease: a public health priority and harbinger of premature cardiovascular diseaseJ Intern Med2010268545646720809922
   PubMed Web of Science ®Google Scholar
• HunterDJGene-environment interactions in human diseasesNat Rev Genet20056428729815803198
   PubMed Web of Science ®Google Scholar
• SmildeTDAsselbergsFWHillegeHLMild renal dysfunction is associated with electrocardiographic left ventricular hypertrophyAm J Hypertens200518334234715797651
   PubMed Web of Science ®Google Scholar
• SmildeTDZuurmanMWHillegeHLRenal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophyAm J Hypertens200720101097110317903694
   PubMed Web of Science ®Google Scholar
• KuznetsovaTStaessenJAThijsLLeft ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretionCirculation2004110172644265015492316
   PubMed Web of Science ®Google Scholar
• OhishiMRakugiHOgiharaTAssociation between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophyN Engl J Med199433116109710987993479
   PubMed Web of Science ®Google Scholar
• SchunkertHControversial association of left ventricular hypertrophy and the ACE I/D polymorphism – is the mist clearing up?Nephrol Dial Transplant1998135110911129623534
   PubMed Web of Science ®Google Scholar
• BrewsterUCPerazellaMAThe renin-angiotensin-aldosterone system and the kidney: effects on kidney diseaseAm J Med2004116426327214969655
   PubMed Web of Science ®Google Scholar
• van der KleijFGSchmidtANavisGJAngiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium statusKidney Int Suppl199763S23S269407415
   PubMed Web of Science ®Google Scholar
• DwivediRSHermanJGMcCaffreyTARajDSBeyond genetics: epigenetic code in chronic kidney diseaseKidney Int2011791233220881938
   PubMed Web of Science ®Google Scholar
• StenvinkelPKarimiMJohanssonSImpact of inflammation on epigenetic DNA methylation – a novel risk factor for cardiovascular disease?J Intern Med2007261548849917444888
   PubMed Web of Science ®Google Scholar
• HarveySJJaradGCunninghamJPodocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular diseaseJ Am Soc Nephrol200819112150215818776121
   PubMed Web of Science ®Google Scholar
• HoJJMarsdenPADicer cuts the kidneyJ Am Soc Nephrol200819112043204618923053
   PubMed Web of Science ®Google Scholar
• ShiSYuLChiuCPodocyte-selective deletion of dicer induces proteinuria and glomerulosclerosisJ Am Soc Nephrol200819112159216918776119
   PubMed Web of Science ®Google Scholar
• HoJNgKHRosenSDostalAGregoryRIKreidbergJAPodocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injuryJ Am Soc Nephrol200819112069207518832437
   PubMed Web of Science ®Google Scholar
• PernaAFIngrossoDSattaELombardiCAcanforaFDe SantoNGHomocysteine metabolism in renal failureCurr Opin Clin Nutr Metab Care200471535715090904
   PubMed Web of Science ®Google Scholar
• KalluriRNeilsonEGEpithelial-mesenchymal transition and its implications for fibrosisJ Clin Invest2003112121776178414679171
   PubMed Web of Science ®Google Scholar
• RashidAIssaJPCpG island methylation in gastroenterologic neoplasia: a maturing fieldGastroenterology200412751578158815521024
   PubMed Web of Science ®Google Scholar
• BechtelWMcGoohanSZeisbergEMMethylation determines fibroblast activation and fibrogenesis in the kidneyNat Med201016554455020418885
   PubMed Web of Science ®Google Scholar
• ParsaAKaoWHXieDAPOL1 risk variants, race, and progression of chronic kidney diseaseN Engl J Med2013369232183219624206458
   PubMed Web of Science ®Google Scholar